Aceon
(perindopril erbumine)PreclinicalSmall molecule
Aceon is one of 44 small molecule programs targeting Fed. It is currently in Preclinical.
2
Indications
3
Total Trials
0
Active Trials
43
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
41 competitors in TED
#DrugCompanyPhaseTrials
1Scemblix
NovartisApproved
Alecensa
RocheApproved
Medrol
PfizerPhase 3
Golytely
BayerPhase 3
Fludara
SanofiPhase 2
Eliquis
Bristol-Myers SquibbPhase 2
Venclexta
AbbViePhase 2
Jakafi
IncytePhase 2
Calquence
AstraZenecaPhase 2
Epkinly
GenmabPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Regulatory
FDA Approval Timeline[4]
Dec 30, 1993
ACEON
NDA NDA020184
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for perindopril erbumine. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- SSymplmed Pharmaceuticals LLC